BRCA-Driven Disparities in Young Black Women Expose Gaps in Genetic Screening Equity

An observational cohort study of 686 Black women diagnosed with invasive breast cancer at or before age 50 across Florida and Tennessee (2005–2018) found that 15.3% carried pathogenic variants, predominantly in BRCA1 and BRCA2, with BRCA1 mutations clustering in triple-negative cases and diagnoses at or before 40. This single-study design, lacking randomization and drawn from two states, limits causal inference and generalizability compared with larger multi-ethnic registries. Original coverage underplays how historical underrepresentation of African ancestry in BRCA discovery cohorts has skewed variant interpretation databases, leading to more variants of uncertain significance in Black patients. Cross-referencing with a 2021 JAMA Oncology analysis of 4,000+ diverse breast cancer cases and a 2023 NCI SEER-linked study of testing uptake reveals persistent 30–40% lower referral rates for Black women despite equivalent or higher mutation prevalence, driven by insurance fragmentation and provider bias rather than family history alone. These patterns compound mortality gaps, as early BRCA identification enables MRI-augmented screening and risk-reducing interventions proven effective in high-risk cohorts. Equitable implementation requires targeted outreach beyond current USPSTF criteria to close the precision-medicine divide.